At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RNA Atrium Therapeutics
Post-Mkt 08-27 16:19:34 EDT
13.98
+0.13
+0.94%
盘后13.98
+0.000.00%
16:10 EDT
High14.09Low13.59Vol119.52K
Open13.78D1 Closing13.85Amplitude3.60%
Mkt Cap239.14MTradable Cap219.78MTotal Shares17.11M
T/O1.67MT/O Rate0.76%Tradable Shares15.72M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Korro to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  08-27 19:00
Korro to Participate in Upcoming Investor Conferences
Circio bolsters board as it advances circular RNA gene therapy platform
TIPRANKS  ·  08-26 01:07
Circio bolsters board as it advances circular RNA gene therapy platform
Press Release: Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and Eur40.25 Million PIPE Financing from New and Existing Investors
Dow Jones  ·  08-24
Press Release: Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and Eur40.25 Million PIPE Financing from New and Existing Investors
BioNTech’s New HIV RNA Vaccine Trial: What Investors Should Watch Now
TIPRANKS  ·  08-22
BioNTech’s New HIV RNA Vaccine Trial: What Investors Should Watch Now
Brii Biosciences Narrows Interim Loss as HBV and RNA Pipelines Advance
TIPRANKS  ·  08-21
Brii Biosciences Narrows Interim Loss as HBV and RNA Pipelines Advance
Atrium Therapeutics Awards New Hire Stock Options for 11,000 Shares at $13.48 Each
Reuters  ·  08-21
Atrium Therapeutics Awards New Hire Stock Options for 11,000 Shares at $13.48 Each
Atrium Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  08-21
Atrium Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines
Reuters  ·  08-20
Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines
One Nation staffer allegedly assaulted at major Australian show‘They were spat on. They were punched.’3 min read
7NEWS  ·  08-17
One Nation staffer allegedly assaulted at major Australian show‘They were spat on. They were punched.’3 min read
Atrium Therapeutics Price Target Maintained with a $25.00/Share by HC Wainwright & Co.
Dow Jones  ·  08-15
Atrium Therapeutics Price Target Maintained with a $25.00/Share by HC Wainwright & Co.
The huge change set to reshape a beloved Australian traditionNew arenas, homes and facilities are coming to a historic precinct with a 150-year legacy.3 min read
7NEWS  ·  08-15
The huge change set to reshape a beloved Australian traditionNew arenas, homes and facilities are coming to a historic precinct with a 150-year legacy.3 min read
Atrium Therapeutics, Inc. (RNA) Receives a Buy from Wells Fargo
TIPRANKS  ·  08-14
Atrium Therapeutics, Inc. (RNA) Receives a Buy from Wells Fargo
Heart Drug Developer Atrium Therapeutics' Q2 Loss Widens as Expenses Rise
Reuters  ·  08-14
Heart Drug Developer Atrium Therapeutics' Q2 Loss Widens as Expenses Rise
Atrium Therapeutics Q2 Basic EPS USD -1.18
THOMSON REUTERS  ·  08-14
Atrium Therapeutics Q2 Basic EPS USD -1.18
Atrium Therapeutics Posts Investor Presentation on Precision RNA Medicines for Cardiac Disease
Reuters  ·  08-14
Atrium Therapeutics Posts Investor Presentation on Precision RNA Medicines for Cardiac Disease
Atrium Therapeutics Posts Q2 R&D Expense of $15.3 Million on Trial Prep, IND-Enabling Work
Reuters  ·  08-14
Atrium Therapeutics Posts Q2 R&D Expense of $15.3 Million on Trial Prep, IND-Enabling Work
Atrium Therapeutics Q2 FY26 Net Loss Widens to $20.19 Million; Revenue Falls to $3 Million
Reuters  ·  08-14
Atrium Therapeutics Q2 FY26 Net Loss Widens to $20.19 Million; Revenue Falls to $3 Million
Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M Estimate
Benzinga Earnings  ·  08-14
Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M Estimate
Atrium Therapeutics, Inc. (RNA) Receives a Buy from H.C. Wainwright
TIPRANKS  ·  08-14
Atrium Therapeutics, Inc. (RNA) Receives a Buy from H.C. Wainwright
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
THOMSON REUTERS  ·  08-13
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

Introduction

Company Name.
Atrium Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Issue price:
--